Financings of the Fortnight Explores the Alternatives

From The IN VIVO Blog
September 19, 2013 - 2:28pm
With all the noise this year about IPOs in our little corner of the world, it’s been easy to forget that most biotechs out there are scrambling for any source of cash they can lay hands on. Assurances aside that traditional biotech VC is making relative bank, the overall pool of traditional venture capital available to invest will continue to dwindle, as respondents in START-UP’s 3rd annual life science VC survey were quite adamant about. (The survey is now available, by the way.) This week we got a taste of the post-VC world; or at least, a reminder of the various types of alternative funding out there for health care and biotech that, in a few years, could replace a significant chunk of traditional venture and interrupt for good the boom-and-bust cycle.First, the elephant in the room: Google announced it would fund a new health care company, Calico, dedicated to anti-aging. The search-and-so-much-more giant is clearly obsessed with health, and doing something about the drastic – dare we say “tragic” – flaws in the care system. Our correspondent Paul Bonanos did a great job delving into Google Ventures’ health care investment strategy in this feature earlier this year, and we recommend reading it (non-subscribers can sign up for a free trial) as background to what might be going on with Calico.Fly-on-wall fantasy: Page: How do we increase Google searches over a person's lifetime? Brin: What if we just increased the lifetime?— Josh Berlin (@BioPharmaJosh) September 18, 2013Paul also reminds us that the Googlers aren’t the only tech-heads with health-care ambitions: Peter Thiel, Yuri Milner and others are shifting their fortunes in small measures. And bully for them; we could certainly use fresh minds and tech-savvy strategies (Tech Tonics?), what with the data-intensive nature of health care these days. But Silicon Valley’s libertarian streak is often at odds philosophically with another important source of biotech funding that we were reminded of this week. The National Institutes of Health announced the recipients of $45 million from the funds dedicated in 2012 to Alzheimer’s research. Those funds aren’t going directly to biotech companies, but the trials and other efforts they’re backing are much needed in an area that seems practically abandoned by industry – at least in proportion to the level of the dire medical need Alzheimer’s represents. So, indirectly, one can only hope the NIH funding can move the needle enough for biopharma, big and small, to see clearer pathways that deserve cash outlays from the private sector, as well.Finally, we’re about to see a small but significant step toward equity crowdfunding. Title II of the JOBS Act, which loosens the rules for general solicitation of accredited investors, takes effect next week. It’s not quite crowdfunding nirvana – or the apocalypse, depending on your viewpoint – because we’re still a ways away from Mom and Pop, Joe Sixpack, and the Joneses being able to participate.  (That’s Title III.) But all manner of folks are lined up, ready to provide investment platforms for those with an eye on biotech, as our colleagues have written about here. If you happen to be at PSA: The Pharmaceutical Strategy Conference in New York next week, you can ask Greg Simon, who’s running the equity crowdfunding site Polliwogg, all about the latest developments. (Or you can catch him on the panel “Funding Biotech: New Ways To Create Value.”) Or, if you hate going anywhere near New York because you’re convinced it’s about to be overrun by giant drooling sea-dragon spiders, well, the people we write about have products that can help you. Until then, relax in the safety of your home or office, avoid the crowds (and their funds), and enjoy the latest edition of….Civitas Therapeutics: From the ashes of the inhaled insulin efforts of the previous decade comes Civitas, which said September 11 it has raised a $38 million Series B financing to fund late-stage development of the company’s lead program, CVT-301, an inhaled formulation of levodopa (L-dopa) to treat debilitating motor fluctuations – known as “off episodes” -- associated with Parkinson’s disease. Civitas spun out of Alkermes' pulmonary business in 2010, then the latest casualty in Big Pharma’s complete retreat from several efforts to create inhaled insulin products. But Longitude Capital and Canaan Partners raised $20 million for a Series A, and in early 201

Continue reading this article »



More Pharma News & Articles »

Pharma Description

The Pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications.


Bidvest  Raeburn  FDA-required  World Data  Reckitt Benckiser  Motrin  Charles Grassley  Andrew Witty  Witty  Health Benefits  Pleas  Glenmark  Indian IP  Psychiatric  PLIVA  Submissions  Medical Devices  Primary Care  Vytorin  Kenneth Frazier  Diovan  Healthcare Informatics  Petition  Flash-based  Eisai  Pennsylvania Superior  Medicinal Products  Human Use  European Medicines Agency  Bristol-Myers  Actelion  Payment Advisory Board  Fosamax ONJ  Alnylam  Drug Administration Safety  Permanent  Zilmax-fed  IMS Health  The Lancet  Bausch  Lomb  Tim Anderson  CAFO  Lanham Act  DOTW  CEO Brent Saunders  ViroPharma  Merial  FOTF  Unfair  CEO Jeremy Levin  Flu  2013*Drugs  Fluoride Action Network  Transparency  Lemtrada  FierceBiotech  Fast Fred Hassan  Nutrients  Found  Not Robots  AmerisourceBergen  Expo West  Payers  Managed  Endo Health Solutions  Valeant Pharmaceuticals  Endo  Series B  Vascepa  Aredia-Zometa  Hematology  SmithKline  Safe  GRAS  Lucy  Charlie Brown  ABPI  CEO Joe Jimenez  Statins  Interactive Data  Electronic  Premarket Approval  CV  Twombly  Beecham  PharmaTimes  Timothy  Soriot  Moderna  Inspector General  Cerner  Jimenez  Elsevier Policy  Enforcement  Happens  HQ  HFCS  Genetically  Growing 

Pharma Blogroll

.Google Health   Alison-bass   Articles.mercola   Biopharmatoday   Biotechblog   Brodyhooked   Businessethicsblog   Cenblog   Druganddevicelaw   Drugchannels   Elsevierbi   Evidenceinmedicine   Eyeonfda   Fairwarning   Fdamatters   Fiercepharma   Hcrenewal   Health Sciences Institute   Health-watched   Healthiertalk   Healthnewsreview   Invivoblog   Ivanho   Medadnews   Nashhealthpolicy   nutraingredients   Nutraingredients-usa   Orangebookblog   Patentbaristas   Patents4life   Pfizer   Pharmalive   Pharmamkting   Pharmaphorum   Pipeline.corante   prescriptionaccess   Researchethicsblog   Retraction-watch   Shearlingsplowed   Social.eyeforpharma   Spicyipindia   Worldofdtcmarketing